LIFE: Interim data analysis of the first in-human study shows that Lifecare’s sensor is able to monitor glucose variations

Conducting clinical trials on humans is a significant step towards Lifecare's
goal of contributing to helping people with diabetes to live a normal life.  

The purpose of the first study is to optimize signal reading from the company's
groundbreaking sensor technology for continuous glucose monitoring for people
with diabetes. The glucose sensor for the clinical trials is produced at the
company's development department in Reutlingen, Germany, and the studies are
conducted at the company's clinical department in Mainz, Germany. 

Lifecare aims to offer continuous glucose monitoring with a sensor that is
significantly smaller and has a function time that is 12 times longer than
existing needle-type glucose sensors. The sensor "Sencell" has the size of a
grain of rice. It will be the first solution for continuous glucose monitoring
that can be fully placed under the skin, without a fixed device on the outside
of the body. Lifecare's solution is expected to be significantly less expensive
than existing glucose monitoring systems. 

Achievements:

As we have underlined in previous communication performing a clinical study with
a novel technology and device never before used by humans is a complex
operation. The primary purpose of the ongoing study is to provide
proof-of-concept confirmation for glucose measurement in humans. 

The data points collected from the early readout in the study show that our
sensor is able to follow glucose variations in humans. Consequently, we will
continue the pilot study based on these encouraging data. 

Lifecare Chief Scientific Officer, Professor Andreas Pfützner states: 
"Our sensor measures glucose in the human interstitial fluid in the subcutaneous
tissue. We have shown a sensitivity that is in line with that of widely used
Continuous Glucose Monitoring systems, which act as a reference measurement in
the study. We have confirmed the functionality that we observed in the animal
trials, and we are going to provide further information once we have more
comprehensive data from this ongoing trial". 

Lifecare Chief Executive Officer Joacim Holter comments:
"This is a major achievement in our development and an important preparation to
further improve the device specifications considering the planned clinical
studies for CE approval." 

Contact: 
Joacim Holter, CEO, tel. +47 40059050, epost: joacim.holter@lifecare.no

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 the Norwegian Securities Trading Act. This stock exchange
announcement was published by Joacim Holter, CEO at Lifecare AS, on 27.9.2022 at
8:38 CET.

____________________

Lifecare AS is a sensor technology company headquartered in Bergen. The company
is developing a sensor that measures variations in glucose levels for people
with diabetes based on changes in osmotic pressure, which are documented to
correlate 100% with changes in the incidence of glucose. Lifecare's technology
and methodology are patented, and the company is believed to be the only player
globally that uses osmotic principles as a basis for accurate and stable
continuous glucose measurement. The technology and method are highly usable and
allow for the measurement of a wide range of molecules in addition to glucose.